Nuclera Expands eProtein Discovery Capabilities to Enable Membrane Protein Production




Nuclera Expands eProtein Discovery Capabilities to Enable Membrane Protein Production

• Membrane proteins synthesized and purified within 48 hours.
• Active membrane transporter, MsbA and integral membrane protein, ZMPSTE24 synthesized

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, today announced the addition of a new membrane protein workflow to its system. This expanded capability enables the expression, purification and stabilization of challenging membrane proteins, which are often key targets in therapeutic development. Using cell-free protein synthesis, digital microfluidics, and optimized additive screening, eProtein Discovery can express and purify functional, correctly folded membrane proteins, in 48 hours.

Membrane proteins play vital roles in regulating cellular processes and many are implicated in the development and progression of disease. 60% of FDA-approved drugs target membrane proteins¹ yet the extraction and stabilization of these structurally complex proteins remains challenging due to their intrinsic hydrophobic nature.

Nuclera demonstrated the capabilities of eProtein Discovery to produce membrane proteins by synthesizing MsbA (a membrane transporter) and ZMPSTE24 (an integral membrane protein)². In 24 hours, eProtein Discovery evaluated different expression and purification conditions, including assessing the effects of using nanodiscs, lipids and detergents, to identify the optimal conditions for producing soluble, stable MsbA and ZMPSTE24. Scale-up production of these membrane proteins was achieved within 48 hours, enabling rapid functional evaluation. MsbA and ZMPSTE24 generated using eProtein Discovery had high-yield, were functionally active, and compatible with cryo-Electron Microscopy (cryo-EM).

Existing eProtein Discovery users can access this new membrane protein production capability through a software update.

Dr Toby Ost, SVP of Product Development, Nuclera, said: “Membrane protein production has long been a technical challenge, often resulting in misfolded or inactive proteins. eProtein Discovery overcomes these challenges, enabling scientists to rapidly produce functional membrane proteins, accelerating drug discovery and structural biology workflows.”

Dr Konstantinos Beis, Reader in Membrane Protein Structural Biology, Imperial College London, added: “The eProtein Discovery System is a welcome new toolkit for membrane protein production. We were commissioned via Imperial Consultants to test the protein quality in our lab – and the early results are promising.”

For more information about Nuclera’s eProtein Discovery system, please visit: https://www.nuclera.com/system/

1. Paper: How many drug targets are there?
2. Poster: Functional Membrane Proteins – Ready in 48 Hours

Contacts

Media contact:
Dr Ben Rutter

Zyme Communications

Tel: +44(0)7920 770 935

Email: ben.rutter@zymecommunications.com

Oxford Nanopore Expands Compatible Products Programme and Strengthens Multi-Omics Ecosystem




Oxford Nanopore Expands Compatible Products Programme and Strengthens Multi-Omics Ecosystem

Multiple new partnerships with approved products announced to support broader access to flexible, end-to-end sequencing applications.

OXFORD, England–(BUSINESS WIRE)–#Nanopore–Oxford Nanopore Technologies today announced the expansion of its Compatible Products Programme (CPP), welcoming a new cohort of leading partners whose products now integrate seamlessly with Oxford Nanopore’s rapid, information-rich, accessible and affordable molecular sensing technology.

First launched in May 2024, the Compatible Products Programme was created to support third-party content development on Oxford Nanopore’s platform. Compatible products provided by trusted partners go through a rigorous validation process, leading to compatible workflows and applications that benefit user experience.

The new organisations include: 10x Genomics, Agilent Technologies, Asuragen, Day Zero Diagnostics, Hamilton Robotics, New England Biolabs (NEB), Opentrons, Pathosense, and Thermo Fisher Scientific. Together, these partners offer a diverse range of tools and solutions – from single-cell and spatial biology platforms to automated sample preparation, potential infectious disease diagnostics, and molecular biology reagents – all designed to enhance the sequencing workflow.

The approved products from these companies have undergone strict evaluation to ensure compatibility with Oxford Nanopore’s multi-omic molecular sensing technology, supporting seamless functionality and optimal performance.

Through the CPP, partners gain access to a shared customer base and a fast-growing community of users in more than 125 countries. For end users, the programme enhances flexibility and seamless workflows, all underpinned by Oxford Nanopore’s rapid, information-rich, and accessible technology.

“As the genomics field continues to evolve at pace, researchers and clinicians are increasingly seeking flexible, complete workflows to enable their science,” said Thomas Bray, VP Business Development, Oxford Nanopore Technologies. “This expanded programme empowers users with more choice and confidence, while opening new opportunities for collaboration across the scientific community.”

The initiative reinforces Oxford Nanopore’s broader commitment to building an open, collaborative ecosystem that enables the analysis of anything, by anyone, anywhere – reducing barriers for researchers and enabling innovation across diverse settings, from high-throughput labs to field-based deployments.

To view the current list of CPP partners and compatible products, please visit:

https://nanoporetech.com/about/partners/nanopore-compatible-products-programme

Quotes:

10x Genomics

“Our customers are tackling the most challenging questions in biology, and they need flexibility in the tools they use. With compatibility between Oxford Nanopore’s long-read sequencing technology and our GEM-X single cell platform, researchers now have more flexibility and choice to unlock deeper transcriptomic insights.”

Day Zero Diagnostics

“We are thrilled to see Keynome Cloud recognised as an Oxford Nanopore compatible product. We believe Oxford Nanopore sequencing coupled with DZD’s regulatory-grade algorithms and databases will deliver a new paradigm for infectious disease diagnostics.”

Hamilton Robotics

“Nanopore Sequencing is an amazing technology for short up to ultra-long read sequencing”

New England Biolabs (NEB)

“NEBNext® & Monarch® for ONT sequencing – sample prep simplified”

PathoSense

“Complete diagnostics of veterinary infectious diseases without prior selection”

About Oxford Nanopore Technologies

Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used in more than 125 countries to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. For more, visit: https://nanoporetech.com/

Contacts

Jacob Rackley

Media@nanoporetech.com

AdvanCell Proudly Announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’




AdvanCell Proudly Announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’

SYDNEY–(BUSINESS WIRE)–AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced $18M in Australian Federal Government Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’.

One out of eight men develops prostate cancer. With the support from the Medical Research Future Fund (MRFF) Frontiers Initiative, the goal of the multidisciplinary multi-institutional investigator team is to transform the clinical management of prostate cancer by leveraging leading therapeutic radiopharmaceutical technology paired innovative clinical development and a deep understanding of tumour biology to improve the lives of patients with prostate cancer.

The research program is enabled by AdvanCell’s proprietary (Lead-212) ²¹²Pb alpha isotope production technology along with the delivery of a first-in-field clinical platform trial to accelerate the translation of ²¹²Pb-based targeted alpha therapies, one of the most exciting breakthroughs in cancer treatment.

Dr. Anna Karmann MD PhD, AdvanCell Chief Medical Officer said: “On behalf of all Co-Investigators, I would like to thank the Australian Government and MRFF Frontiers Initiative committee for this prestigious award. Targeted alpha therapies are among the most promising in oncology. We believe this MRFF-funded research can be practice changing and have a lasting positive impact on the lives of patients with prostate cancer. We highly value the support and opportunity this funding provides to fast-track translation and accelerate the development of novel combination therapies in an industry-academic partnership.”

AdvanCell is collaborating with world-leading experts in Australia and globally, underpinning the transformative nature of the important clinical research. The clinical PIs include internationally renowned physician scientists Prof. Louise Emmett (St Vincent’s Hospital, Sydney and University of New South Wales) and Prof. Shahneen Sandhu (Peter MacCallum Cancer Centre, Melbourne).

Prof. Louise Emmett: “This collaborative Frontiers grant gives us the tools to deeply evaluate optimal combinations with targeted alpha therapy in prostate cancer – aiming for longer better lives using great technology in a smart way.”

Prof. Shahneen Sandhu: “Our MRFF grant will accelerate the development of innovative targeted alpha therapy combinations designed to enhance patient care and clinical outcomes.”

Scientific investigators include Prof. Richard Payne (The University of Sydney), Prof. Matt Trau, Dr. Alain Wuethrich, Dr. Kevin Koo (The University of Queensland), Dr. Scott Lovell (University of Bath), A/Prof. Serigne Lo (Melanoma Institute Australia) and Dr. Thomas Kryza and Dr. Simon Puttick (AdvanCell).

Prof. Stephen Rose, Head of Translational Medicine and Clinical Science at AdvanCell, highlighted the importance of the MRFF funding. “The MRFF funding supports Australian innovation to drive the establishment of sovereign manufacturing capabilities to accelerate clinical translation of ²¹²Pb-targeted alpha therapy.”

About AdvanCell

AdvanCell is dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By combining advanced manufacturing capabilities with cutting-edge science and clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for cancer patients globally. For more information, visit www.advancell.com.au.

Contacts

For media inquiries, please contact:

Andrew Adamovich

CEO

Email: contact@advancell.com.au
Phone: +612 8000 4199

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)




Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Exicure, Inc. (Nasdaq: XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor.

Exicure, Inc. (“Exicure”) is planning for a clinical trial in Acute Myeloid Leukemia (AML) with GPC-100. The company believes that GPC-100, when paired with modern AML treatment regimens, can further improve outcomes in this high unmet need clinical indication. A Phase 1 chemosensitization study involving 15 patients with relapsed or refractory AML was previously conducted by Taigen, the original developer of GPC-100. In that study, GPC-100 was combined with fludarabine and cytarabine to evaluate safety and preliminary efficacy. Preclinical data published by Dr. Pam Becker at City of Hope in collaboration with GPCR Therapeutics USA, a subsidiary of Exicure, demonstrated that dual inhibition of CXCR4 with GPC-100 and beta-2 adrenergic receptor blockade led to improved chemotherapy response (2024 American Society of Hematology Annual meeting : Poster #2758). This therapeutic approach is protected by an expanded patent portfolio granted in the United States, Japan, Australia, and Taiwan.

In addition to AML, GPC-100 is currently being evaluated in an ongoing Phase 2 trial in patients with multiple myeloma (MM) undergoing autologous stem cell transplant (ASCT; NCT05561751). Clinical trial results for this study are expected in Q4 2025.

Current Evaluating Potential Indication Expansions – In addition to AML and MM, Exicure is evaluating a range of potential indications for GPC-100, including sickle cell disease, pediatric oncology, and cell and gene therapy settings.

About Exicure, Inc.

Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. For further information, see www.exicuretx.com.

Contacts

Media Contact:
Sarah Ellinwood, PhD

Kendall Investor Relations

sellinwood@kendallir.com

ZYUS Life Sciences Corporation Announces Issuance of Bonus Warrants Pursuant to Loan Agreements




ZYUS Life Sciences Corporation Announces Issuance of Bonus Warrants Pursuant to Loan Agreements

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, announces that it has received conditional acceptance from the TSX Venture Exchange (the “Exchange”) to issue certain common share purchase warrants to independent directors of the Company (“Lenders”) in connection with the issuance and amendment of certain unsecured loans announced in its previous press releases of March 10, 2025 and March 17, 2025.

As previously announced on March 10, 2025, unsecured loans between the Company and one of its independent directors entered on October 1, November 5 and December 20, 2024 (the “Prior Unsecured Loans”) had their maturity dates of April 1, May 5, and June 20, 2025, respectively, extended to March 28, 2027. Additionally, the director also advanced an additional unsecured loan (“Loan 1”) to the Company in the amount of CAD$1,500,000. In exchange for amending the maturity dates of the Prior Unsecured Loans and advancing Loan 1, the director received an aggregate of 4,875,000 common share purchase warrants having an expiry date of April 11, 2027, subject to the acceleration conditions described in the Company’s March 10, 2025 press release. Each warrant entitles the director to acquire one common share of the Company at an exercise price of $0.80 per common share until the expiry date. The warrants and any shares issuable on exercise thereof are subject to a statutory hold period expiring on August 12, 2025 in accordance with applicable Canadian securities law.

As announced on March 17, 2025, a promissory note agreement having a maturity date of August 27, 2025 (the “Promissory Note”) previously entered between the Company’s wholly-owned subsidiary, ZYUS Life Sciences Inc., and a second independent director of the Company was amended and replaced by a loan agreement (“Loan 2”) between the Company and the director. Pursuant to Loan 2, this director advanced to the Company additional cash consideration of $0.25 million and $0.025 million of accrued but unpaid interest under the Promissory Note was capitalized and added to the principal amount of Loan 2 for a total of $0.375 million, increasing the principal amount owing to the director from $0.1 million to $0.375 million and extending the maturity date from August 27, 2025 to March 28, 2027. In exchange for extending the maturity date and advancing additional cash consideration, the director received an aggregate of 281,250 common share purchase warrants having an expiry date of April 11, 2027, subject to the acceleration conditions described in the Company’s March 17, 2025 press release. Each warrant entitles the director to acquire one common share of the Company at an exercise price of $0.80 per common share until the expiry date. The warrants and any shares issuable on exercise thereof are subject to a statutory hold period expiring on August 12, 2025 in accordance with applicable Canadian securities law.

The issuance of warrants constitutes a “related party transaction” as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”) as lenders are each directors of the Company. The Company has relied on the exemption from the valuation requirement pursuant to section 5.5(b) (Issuer Not Listed on Specified Markets) of MI 61-101 and from the minority shareholder approval requirement prescribed by section 5.7(1)(a) (Fair Market Value Not More Than 25 Percent of Market Capitalization) of MI 61-101 respecting issuance of the warrants.

About ZYUS Life Sciences Corporation

ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS’ unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients’ lives. For additional information, visit www.zyus.com or follow us on X (formerly known as Twitter) @ZYUSCorp.

Cautionary Note Regarding Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the Company’s business, the Company’s ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids and acceleration of the exercise period of the warrants. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans”, “will” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company’s business, the Company’s ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates, and introduce products that act as alternatives to current pain management therapies such as opioids, and acceleration of the exercise period of the warrants are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Contacts

ZYUS Media Inquiries

media@zyus.com
1-833-651-7723

ZYUS Investor Relations

investors@zyus.com

Sphere Bio Expands APAC Distribution Network to Strengthen Presence in Region




Sphere Bio Expands APAC Distribution Network to Strengthen Presence in Region

Operational scale-up accelerates global growth strategy to increase regional access and technical support

CAMBRIDGE, England–(BUSINESS WIRE)–Sphere Bio, a leading provider of picodroplet-based microfluidics for functional single-cell analysis and isolation, today announced a significant expansion of its APAC distributor network. This development marks a key milestone in the Company’s global commercial strategy to meet growing demand for its next-generation single-cell analysis platforms.

The expansion enhances Sphere Bio’s footprint across key Asian and Pacific markets, improving regional access to its innovative technologies, local support, and technical expertise. The Company has formed partnerships with five new distributors: 1st PhileKorea (South Korea), AS ONE Corporation (Japan), Decode Science (Australia and New Zealand), Everlife Research Instruments (Singapore), and Premas Life Sciences (India and Bangladesh). These new partnerships join an already robust network, including Bang Trading (Thailand), Cold Spring Biotech (Taiwan), and Gene Company (China and Hong Kong).

This strategic scale-up enhances Sphere Bio’s ability to provide localized product support and increase adoption of its growing technology portfolio, including the recently launched Cyto-Mine^® Chroma platform and new assay offerings. The investment in new partnerships reflects the Company’s long-term commitment to serving the region and supporting local customers with in-depth expertise.

Dale Levitzke, CEO, Sphere Bio, commented: “2025 is a pivotal year as we scale to meet growing global demand and enter high-growth markets. We have partnered with best-in-class distributors to extend our reach and bring our transformative solutions to more customers worldwide. This expansion supports our mission to accelerate scientific discovery through innovation in single-cell analysis.”

Jay Manikandan, VP Commercial (APAC), Sphere Bio, added: “Our expanded distributor network and enhanced presence reflects our commitment to providing localized customer and technical support across the APAC region. These developments represent an important step in bringing our solutions closer to researchers and advancing global adoption.”

To learn more about Sphere Bio’s integrated life sciences tools and solutions, please visit spherebio.com/our-products

Contacts

For further information please contact:
Dr Claire Cox

Sphere Bio Ltd.

Tel: +44 (0)7365 209 441

Email: claire.cox@spherebio.com

Zyme Communications
Lily Jeffery

Tel: +44 (0)7891 477 378

Email: lily.jeffery@zymecommunications.com

Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin




Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin

• Continued strong performance in Reproductive Medicine which exceeded sales of €1 billion for the first time

• Adstiladrin^® (nadofaragene firadenovec-vncg), our novel gene-based therapy for bladder cancer, emerged as a second growth driver following the first full year of U.S. sales

• Commitment to sustainability highlighted by supply of 1.5 million doses of Carbetocin Ferring (carbetocin, room temperature-stable formulation) to reduce maternal deaths in low- and lower-middle-income countries

SAINT-PREX, Switzerland–(BUSINESS WIRE)–Ferring achieved total revenues of €2.3 billion in 2024, an increase of 7% over the previous year at actual exchange rates (AER) and 8% at constant exchange rates (CER). This above market growth reflected the continued strong performance in Reproductive Medicine, which exceeded €1 billion in global sales for the first time. In addition, 2024 was the first full year of U.S. sales of Adstiladrin, our novel gene-based therapy for bladder cancer.

Operating expenses were carefully managed while prioritising investment in growth opportunities, such as Adstiladrin. This resulted in an overall cost reduction of -3% (at AER and CER). Consequently, operating profit reached €192 million, an increase of 38% over the previous year (at AER, +43% at CER).

Jean-Frédéric Paulsen, Chairman of the Board of Directors, said: “For Ferring, this was a year of both continuity and change as we drew on the company’s strengths while evolving our approach to the business. In our core area of Reproductive Medicine, the demand for our products was greater than ever, reflecting worldwide concern about falling birthrates. At the same time, Adstiladrin, a highly innovative gene therapy, emerged as another main driver of growth for the company. Our focus has been to maximise our impact, as we pursue our ambition to unlock opportunities to deliver life-changing solutions to patients at every stage of life.”

Ferring maintained its commitment to protecting the environment, creating value for society, and upholding high standards of responsible and ethical business governance. As part of our commitment to social responsibility, we continued making progress with our Project Family: Safe Birth initiative, aimed at reducing maternal deaths in some of the world’s most underserved communities. In 2024, we supplied 1.5 million doses of our life-saving medicine, heat-stable Carbetocin Ferring, at an affordable access price to low- and lower-middle-income countries, an increase of around 50% over the previous year. With respect to the environment, we reduced Scope 1 and 2 greenhouse gas (GHG) emissions by 9.5%, ahead of our goal of 3%.

These and other achievements are detailed in our 2024 Annual Report and Sustainability Report.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology, and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries.

Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram, YouTube, Facebook and X.

Contacts

For more information, please contact

Carine Julen

Senior Manager, Corporate Communications & Public Affairs

+41 76 301 0178 (mobile)

carine.julen@ferring.com

PureTech Appoints Peel Hunt as Joint UK Corporate Broker




PureTech Appoints Peel Hunt as Joint UK Corporate Broker

BOSTON–(BUSINESS WIRE)–PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), is pleased to announce that it has appointed Peel Hunt as Joint UK Corporate Broker alongside UBS.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech’s R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

Contacts

PureTech
Public Relations

publicrelations@puretechhealth.com
Investor Relations

IR@puretechhealth.com

Fasikl Announces Breakthrough Pivotal Data Demonstrating Superiority of Felix NeuroAI Wristband over Sham Device for Essential Tremor




Fasikl Announces Breakthrough Pivotal Data Demonstrating Superiority of Felix NeuroAI Wristband over Sham Device for Essential Tremor

—Wristband is a first-of-its-kind investigational wearable designed to provide dynamic, all-day, personalized relief for people with essential tremor (ET); powered by advanced AI to continuously adapt stimulation based on real-time feedback—

—TRANQUIL study results presented in late-breaker at the 2025 American Academy of Neurology (AAN) annual meeting demonstrate clinically meaningful improvements in ET symptoms and ability to perform daily activities—

SAN DIEGO–(BUSINESS WIRE)–Fasikl, a trailblazing neuro-AI company redefining the intersection of advanced bioelectronic medicine and artificial intelligence (AI), today announced that its pivotal TRANQUIL study met its primary endpoint of superiority for the company’s Felix™ NeuroAI™ wristband over a sham device. The Felix wristband significantly reduced tremors and showed statistically and clinically significant improvement in the users’ ability to perform daily activities compared to those using the sham device.

“This wearable technology delivered significant improvement in tremor, with both clinicians and patients more likely to report benefit by the end of the study,” said Rajesh Pahwa, M.D., Laverne and Joyce Rider Professor of Neurology at the University of Kansas School of Medicine, Director of the Movement Disorder Program at The University of Kansas Health System, and the principal investigator for TRANQUIL. “The TRANQUIL study represents what could be a shift in how we approach essential tremor treatment, a condition for which new options are sorely needed. Although oral medications are often used to treat essential tremor, they can be frequently unsatisfactory, and while deep brain stimulation and focused ultrasound are effective, they require surgical intervention.”

At the end of the 90-day period the Felix group showed clear superiority over the sham group.

• The Felix group experienced a statistically and clinically significant improvement in ET treatment, with a mean reduction of 6.9 points in modified Activities of Daily Living (mADL) scores compared to 2.7 points in the sham group (P < 0.0001).
• Nearly two-thirds of participants using Felix achieved at least a 20% reduction in mADL scores versus just one-quarter in the sham group.
• Efficacy benefits were consistent across age, gender, tremor severity, and ET medication use.

Secondary outcomes further highlighted the impact of Felix. Both clinicians and patients reported greater symptom improvement with Felix, and quality of life scores improved more substantially in the treatment group. Importantly, no serious device-related adverse events were reported, confirming the device’s strong safety profile.

The Felix NeuroAI Wristband is a first-of-its-kind investigational wearable designed to deliver all-day, personalized relief for people with ET. Powered by advanced AI, Felix continuously adapts stimulation based on real-time feedback, providing dynamic, individualized therapy. Unlike surgical or pharmacologic interventions, Felix is non-invasive and wearable, connecting seamlessly to Fasikl’s cloud-based AI platform for ongoing optimization and learning.

“The TRANQUIL study marks a breakthrough as the first multicenter, double-blind, sham-controlled, non-surgical randomized controlled trial in essential tremor to meet its primary endpoint in over two decades,” said Zhi Yang, Ph.D., CEO of Fasikl. “Felix is a transformative advancement in AI-powered therapeutics, offering a safe, non-invasive, and personalized treatment option for ET patients and their physicians. With the efficacy and safety of Felix now validated and presented, we believe this represents a pivotal moment in the treatment of essential tremor and the broader landscape of movement disorders.”

About Essential Tremor (ET)

Essential tremor (ET) is the most common type of tremor disorder, affecting approximately 7 million people in the United States.¹ It causes involuntary, rhythmic shaking, most often in the hands, which can make everyday activities like drinking from a glass or tying shoelaces difficult.² Over time, ET can worsen and significantly impact a person’s quality of life.²

The TRANQUIL Study

The TRANQUIL study, a randomized, double-blind, sham-controlled clinical trial, enrolled 125 adults across 12 clinical sites in the U.S. and China. Participants were randomized 2:1 to receive either the Felix™ NeuroAI™ Wristband or a sham device and wore it during waking hours for 90 days. The study’s primary endpoint was change in the modified Activities of Daily Living (mADL) score from the Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS), a commonly used tremor assessment that combines 10 activities of daily living (ADLs) and 2 clinical assessments of tremor.³ The mADL has a maximum score of 52.

About Fasikl

Based in Minneapolis, Fasikl, Inc. is a pioneering neuro-AI company dedicated to developing advanced, AI-powered neural technologies. A 2019 spin-off from the University of Minnesota, Fasikl leverages its proprietary platform to capture neural signals directly from peripheral nerves, enabling intelligent, adaptive therapy. The company is on a mission to transform the treatment landscape for movement disorders, paralysis, and other neurological impairments through cutting-edge neuromodulation innovations. Fasikl’s portfolio, currently under FDA review, includes the Felix™ NeuroAI™ Wristband and the MindForce™ Nerve-Computer Interface. To learn more, visit fasikl.com.

References:

1. Louis ED, Ottman R. How many people in the USA have essential tremor? Deriving a population estimate based on epidemiological data. Tremor Other Hyperkinet Mov (N Y). 2014;4:259. https://doi.org/10.7916/D8TT4P4B
2. Mayo Foundation for Medical Education and Research. (2025, March 15). Essential tremor. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/essential-tremor/symptoms-causes/syc-20350534
3. Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos JL, Lewitt P, Lyons K, Ondo W, Pahwa R, Sethi K, Stover N, Tarsy D, Testa C, Tintner R, Watts R, Zesiewicz T. Reliability of a new scale for essential tremor. Mov Disord. 2012 Oct;27(12):1567-9.

Contacts

Media Contact:
Jenna Kane

Health+Commerce

480-388-9587

jennakane@healthandcommerce.com

New Coalition Calls for Urgent Action to Address Rising Stroke Crisis




New Coalition Calls for Urgent Action to Address Rising Stroke Crisis

GENEVA–(BUSINESS WIRE)–#StrokeActionNow–Launching today, the world’s first multisector advocacy movement dedicated to stroke – the Global Stroke Action Coalition – has issued an urgent call to action to address growing inequities in stroke. Already a leading cause of death and disability, without intervention, the global burden of stroke is projected to rise by a further 50% over the next 25 years, claiming 100 million lives and costing US$1.6 trillion each year.

At this afternoon’s launch, health and economic policy specialists, clinical experts and people with lived experience of stroke, will highlight key data and recommendations for action to address human and financial impact of stroke. Drawing on both data and the lived experiences of people affected by stroke, the Coalition will share their inaugural policy document Stroke Action Now which sets out evidence-based examples of interventions that can significantly advance progress on a disease that is largely:

• Preventable: 80% of the current stroke burden is linked to 10 modifiable risk factors. Identifying and managing hypertension alone could cut the rate of stroke in half.
• Treatable: Advances in clot removal and clot-busting technologies (thrombectomy and thrombolysis) can dramatically improve patient health outcomes, minimizing disability and reducing the economic impact of stroke.
• Recoverable: Access to rehabilitation helps people regain independence and reduces the risk —and cost— of long-term disability.

Despite the clear opportunities, prevention, treatment and rehabilitation services are only available to a fraction of stroke patients. For example, only 3% of medically eligible patients currently receive thrombectomy, with 20-40% of healthcare settings worldwide yet to implement basic stroke rehabilitation services.

“The global burden of stroke has doubled in the past 30 years,” explains Coalition co- Chair, Professor Bo Norrving. “During that same period huge advances have been made across the care pathway that offer us an incredible opportunity to reduce inequitable health outcomes and make significant progress towards global health and development targets. Committing to the development of National Stroke Plans should be a key priority for governments as part of their forward strategy for prevention and control of NCDs. We can’t afford to wait another 30 years to turn this around. Millions of lives depend on governments taking action now.”

Coalition leaders are calling on governments attending the 4th High-Level UN Meeting on NCDs in September this year, to commit to five actions:

1. Making stroke a priority in NCD prevention and control strategies so that it becomes an explicit and integral part of national and internal health agendas.

2. Developing National Stroke Action Plans that address the entire care pathway and include measurable targets that respond to in-country needs.

3. Committing to funding evidence-based interventions and exploring innovative financing models, such as taxing harmful substances, to build domestic resources.

4. Implementing robust stroke monitoring systems that measure changes in the stroke burden and the provision and outcomes of stroke care.

5. Including stroke survivors and caregivers in policy development and prioritize meaningful representation at all levels of decision-making.

The Coalition’s call comes at a defining moment. The upcoming UN High-Level Meeting is a rare opportunity for world leaders to shape the next 25 years of action on NCDs. Stroke must not be overlooked. The Coalition urges governments to seize this moment and ensure that stroke is recognized, prioritized, and acted upon.

Notes

Members of the Coalition include the World Stroke Organization, American Stroke Association, Asia Pacific Stroke Organization, Bayer, Boehringer Ingelheim, European Stroke Organisation, Heart & Stroke Foundation South Africa, Ipsen, March of Dimes Canada, Medtronic, Philips, Stroke Association UK and Society of Vascular and Interventional Neurology.

Contacts

strokecoalition@infinitycommunications.ch